Israel Englander Lexicon Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,398,876 shares of LXRX stock, worth $1.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,398,876

Previous 597,321 134.19%

Holding current value

$1.13 Million

Previous $1 Million 118.94%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.51 - $2.39 $1.21 Million - $1.92 Million	801,555 Added 134.19%	1,398,876 $2.2 Million
Q2 2024 Aug 14, 2024	BUY	$1.54 - $2.28 $97,230 - $143,952	63,137 Added 11.82%	597,321 $1 Million
Q1 2024 May 15, 2024	SELL	$1.3 - $3.58 $1.43 Million - $3.93 Million	-1,098,992 Reduced 67.29%	534,184 $1.28 Million
Q4 2023 Feb 14, 2024	SELL	$1.0 - $1.53 $1 Million - $1.53 Million	-1,000,997 Reduced 38.0%	1,633,176 $2.5 Million
Q2 2023 Aug 14, 2023	BUY	$2.15 - $3.49 $5.61 Million - $9.11 Million	2,610,329 Added 10947.53%	2,634,173 $6.03 Million
Q1 2023 May 15, 2023	SELL	$1.99 - $2.68 $2.29 Million - $3.09 Million	-1,152,723 Reduced 97.97%	23,844 $58,000
Q4 2022 Feb 14, 2023	BUY	$1.8 - $2.56 $487,180 - $692,879	270,656 Added 29.88%	1,176,567 $2.25 Million
Q3 2022 Nov 14, 2022	BUY	$1.94 - $3.43 $1.33 Million - $2.36 Million	687,963 Added 315.65%	905,911 $2.17 Million
Q2 2022 Aug 15, 2022	SELL	$1.31 - $2.69 $197,424 - $405,399	-150,706 Reduced 40.88%	217,948 $405,000
Q1 2022 May 16, 2022	BUY	$1.95 - $3.89 $221,356 - $441,577	113,516 Added 44.49%	368,654 $770,000
Q4 2021 Feb 14, 2022	BUY	$3.81 - $6.16 $674,754 - $1.09 Million	177,101 Added 226.94%	255,138 $1.01 Million
Q3 2021 Nov 15, 2021	SELL	$3.38 - $5.35 $344,144 - $544,726	-101,818 Reduced 56.61%	78,037 $375,000
Q2 2021 Aug 16, 2021	SELL	$4.12 - $5.87 $15,787 - $22,493	-3,832 Reduced 2.09%	179,855 $826,000
Q1 2021 May 17, 2021	SELL	$3.45 - $9.09 $2.57 Million - $6.77 Million	-744,486 Reduced 80.21%	183,687 $1.08 Million
Q4 2020 Feb 16, 2021	BUY	$1.05 - $3.67 $839,217 - $2.93 Million	799,255 Added 619.97%	928,173 $3.17 Million
Q3 2020 Nov 16, 2020	BUY	$1.44 - $2.1 $185,641 - $270,727	128,918 New	128,918 $186,000
Q1 2020 May 14, 2020	SELL	$1.8 - $4.28 $2.36 Million - $5.61 Million	-1,309,722 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.16 - $5.15 $281,533 - $458,828	89,093 Added 7.3%	1,309,722 $5.44 Million
Q3 2019 Nov 14, 2019	BUY	$1.2 - $6.66 $1.42 Million - $7.89 Million	1,184,819 Added 3308.63%	1,220,629 $3.67 Million
Q2 2019 Aug 15, 2019	SELL	$5.35 - $7.11 $6.05 Million - $8.05 Million	-1,131,727 Reduced 96.93%	35,810 $225,000
Q2 2019 Aug 14, 2019	BUY	$5.35 - $7.11 $6.01 Million - $7.99 Million	1,123,929 Added 2577.35%	1,167,537 $36.9 Million
Q1 2019 May 14, 2019	SELL	$4.36 - $7.94 $224,805 - $409,394	-51,561 Reduced 54.18%	43,608 $242,000
Q4 2018 Feb 14, 2019	BUY	$6.15 - $10.51 $72,951 - $124,669	11,862 Added 14.24%	95,169 $632,000
Q3 2018 Nov 14, 2018	SELL	$10.32 - $13.06 $3.57 Million - $4.52 Million	-346,046 Reduced 80.6%	83,307 $889,000
Q2 2018 Aug 14, 2018	BUY	$7.8 - $13.69 $3.35 Million - $5.88 Million	429,353 New	429,353 $5.15 Million
Q1 2018 May 15, 2018	SELL	$7.86 - $11.39 $3 Million - $4.34 Million	-381,266 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$8.77 - $12.28 $22,845 - $31,989	-2,605 Reduced 0.68%	381,266 $3.77 Million
Q3 2017 Nov 14, 2017	BUY	$12.17 - $16.3 $4.67 Million - $6.26 Million	383,871	383,871 $4.72 Million

Others Institutions Holding LXRX

# of Institutions

141

Shares Held

238M

Call Options Held

459K

Put Options Held

133K

View Full List

About LEXICON PHARMACEUTICALS, INC.

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $153M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

More about LXRX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account